HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
AIM ImmunoTech Inc. (AIM)
2.1  0.06  (2.94%) 01-20 02:39
Open: 2.08 High: 2.11
Pre.close: 2.04 Low: 2.03
Volume: 1,465,304 Ave vol: 1,841,933
52w High: 7.11 52w Low: 0.75
MA(50): 1.921 MA(200): 2.231
EPS: -5.873 P/E Ratio: 0
Company profile
Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Website: http://www.hemispherx.net/
Market Cap (M): 85
Shares Out (M): 41
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. The company is headquartered in Ocala, Florida and currently employs 31 full-time employees. The firm is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The firm's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The firm's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.
Technical analysis
Overall: Outperform
MA: Bullish MACD: Bullish
KDJ: Bullish RSI: Bullish
Target 1: 2.80 Target 2: 3.27
Resist 1: 2.40 Resist 2: 2.80
Support 1: 1.97 Support 2: 1.71
Company key metrics
Revenue per Share: 0.0384
Net Income per Share: -2.617
Cash per Share: 0.4035
Book Value per Share: 3.5432
Price to Sales: 26.2796
Price to Book Value: 0.2851
Earnings Yield: -2.5911
Dividend Yield: 0
Debt to Equity: 0.5665
Debt to Assets: 0.3616
Financial analysis
Price to Book Value: Outperform
Return on Assets: Neutral
Return on Equity: Neutral
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Neutral
Stock Charts

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.